Genz-112638: Phase III started

Genzyme began the open-label, active-controlled Phase III ENCORE trial to evaluate 50, 100 or 150 mg oral Genz-112638 given twice daily vs. Cerezyme imiglucerase for 9 months in about 96 patients who ...